Emricasan: Phase II started
Conatus began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 25 mg oral emricasan twice daily for 3 months in about 80 patients with liver cirrhosis. Patients who complete the treatment period may receive emricasan in an open-label period for an additional 3 months. Top-line data are slated for 2H15. Emricasan is also in a Phase II trial in patients with cirrhosis and portal hypertension, with top-line data slated for 3Q15; a Phase IIb trial to treat acute-on-chronic liver failure (ACLF), with data slated for 4Q14; a Phase IIb trial in post-liver transplant HCV patients with unresolved fibrosis, with interim data expected in 1H15; and a Phase II trial to treat non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), with data slated for 1Q15. ...